SELLAS’ CDK9 inhibitor SLS009 (tambiciclib) previously delivered a 33% overall response rate across evaluable relapsed/refractory AML patients, rising to 40% at the recommended 30 mg twice-weekly dose. Subgroup signals included 44% ORR in AML with myelodysplasia-related changes and 50% ORR in ASXL1-mutated AML-MR and M4/M5 subtypes. Median overall survival reached 8.8 months at 30 mg BIW, and 8.9 months in AML-MR versus 2.4 months on best available therapy in an external benchmark.
The company has now enrolled the first patient in a randomized Phase 2 trial in newly diagnosed, first-line AML, aiming to capture patients who are least likely to benefit from the venetoclax/azacitidine backbone. The study plans to recruit about 80 patients in the US and Europe into two defined cohorts: those prospectively identified by a biomarker algorithm as unlikely to respond to venetoclax/azacitidine, and patients who begin on that regimen but show confirmed non-response after two cycles. The protocol will deploy SELLAS’ transcriptomic, genomic, and proteomic models, with topline data expected in Q4 2026 (NCT04588922).
Strategically, this is an upstream expansion designed to ride the center of gravity in AML therapy, where venetoclax-based doublets dominate but resistance and early primary failure remain stubborn. Rather than chase broader frontline use, SELLAS is carving out a precision-enriched niche at the point of venetoclax vulnerability. Mechanistically, CDK9 inhibition could counter venetoclax resistance by suppressing short-lived survival proteins, but the real pivot here is operational and regulatory: preselecting patients least likely to benefit from standard therapy to concentrate effect size and align with FDA’s encouragement of enrichment where biology is well defined.
For sites and CROs, the design raises immediate execution questions. The predictive cohort depends on upfront molecular profiling with tight turnaround times, central lab coordination, and reliable data pipelines to run an algorithm that must be locked, reproducible, and audit-ready. The early resistance cohort requires rapid marrow assessments after cycle two and fast-track randomization, stressing scheduling, pathology bandwidth, and cross-functional handoffs. Vendors that can integrate NGS, transcriptomics, and decision-support into eSource and randomization systems will be critical, as will harmonizing eligibility adjudication across US and EU centers to avoid drift in “non-response” definitions.
Regulators will focus on whether the biomarker model is prespecified, independently validated, and stable across platforms, and whether the randomization framework cleanly isolates the contribution of the CDK9 add-on relative to venetoclax/azacitidine alone. Safety will be scrutinized in a frail frontline population where triplets routinely magnify myelosuppression and hospitalization risk. Payers, if the signal holds, will look for consistent benefit across heterogeneous molecular subsets and operational feasibility of the selection workflow in routine practice.
Key watch items are the control arm structure and primary endpoint selection, the operational definition and central adjudication of early non-response, and tolerability of the triplet at 30 mg BIW in newly diagnosed patients. The sample size signals a hypothesis-testing study rather than a registrational attempt; any path to approval would likely require a larger, prospectively enriched Phase 3. Timing also intersects with a shifting frontline landscape as menin-based combinations and other add-ons mature, raising the bar for incremental benefit and complicating comparator relevance. If SELLAS can validate its selection model and reproduce the r/r efficacy without compromising safety, it will have a credible case to advance into pivotal development; if not, the field’s momentum toward other targeted triplets could quickly narrow the window for CDK9 in AML frontline care.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
